Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Short term Debt (2016 - 2022)

Lexaria Bioscience's Short term Debt history spans 8 years, with the latest figure at $7906.0 for Q2 2022.

  • For Q2 2022, Short term Debt rose 497.13% year-over-year to $7906.0; the TTM value through May 2022 reached $7906.0, up 497.13%, while the annual FY2021 figure was $7926.0, N/A changed from the prior year.
  • Short term Debt for Q2 2022 was $7906.0 at Lexaria Bioscience, roughly flat from $7875.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $206806.0 in Q1 2021 and bottomed at $1324.0 in Q2 2021.
  • The 5-year median for Short term Debt is $8518.0 (2018), against an average of $31646.4.
  • The largest annual shift saw Short term Debt plummeted 98.02% in 2018 before it surged 12825.38% in 2021.
  • A 5-year view of Short term Debt shows it stood at $21654.0 in 2018, then surged by 71.79% to $37200.0 in 2019, then skyrocketed by 134.37% to $87185.0 in 2020, then plummeted by 90.91% to $7926.0 in 2021, then fell by 0.25% to $7906.0 in 2022.
  • Per Business Quant, the three most recent readings for LEXX's Short term Debt are $7906.0 (Q2 2022), $7875.0 (Q1 2022), and $7926.0 (Q3 2021).